Immunogenicity and safety of the booster BNT162b2 vaccine in patients with axial spondyloarthritis treated with biological disease-modifying drugs
Article
[키워드] acute respiratory syndrome
adverse event
antibody concentration
axial spondyloarthritis
biological disease-modifying drug
BNT162b2
BNT162b2 vaccine
booster
booster doses
booster vaccination
clinical questionnaire
Cohort
cohorts
comparable
coronavirus disease
Coronavirus-2
COVID-19
enrolled
evaluated
Evidence
flow cytometric
General population
healthy control
humoral
IL-17
immune response
Immune-mediated inflammatory disease
immunogenicity
individuals
inhibitor
inhibitors
intracellular cytokine
investigated
male
no difference
outcome
Patient
patients
patients treated
peptide-based
persistence
prospective observational study
Responder
Safety
SARS-CoV-2
Specific
spondyloarthritis
subgroups
T-cell
T-cell immune response
T-cell Response
therapy
TNFα
treated
tumor necrosis factor-alpha
vaccination
virus-neutralizing antibody
were assessed
[DOI] 10.3389/fimmu.2022.1010808 PMC 바로가기
[DOI] 10.3389/fimmu.2022.1010808 PMC 바로가기